-
1.发明公开Treatment of pediatric acute lymphoblastic leukemia 有权Behandlung vonpädiatrischerakuter lymphatischerLeukämie
公开(公告)号：EP2918604A1
公开(公告)日：2015-09-16
申请号：EP15154416.0
申请日：2009-11-06
发明人： Zugmaier, Gerhard
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2809 , C07K16/3061 , C07K16/468
摘要： The present invention relates to a method for the treatment, amelioration or elimination of pediatric acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to a pediatric ALL patient in the need thereof.
摘要翻译： 本发明涉及一种用于治疗，改善或消除儿科急性淋巴细胞白血病（ALL）的方法，所述方法包括向需要的儿科ALL患者施用包含CD19xCD3双特异性单链抗体构建体的药物组合物。
-
公开(公告)号：EP3531133A1
公开(公告)日：2019-08-28
申请号：EP18213926.1
申请日：2015-05-20
发明人： Zugmaier, Gerhard , Kufer, Peter , Alekar, Shilpa
IPC分类号： G01N33/574
摘要： The present invention relates to a method for risk-stratifying subjects suffering from B-precursor acute lymphoblastic leukemia (ALL), wherein said subjects are intended for a therapy comprising administration of a CD3 binding domain. Risk-stratification is based on the determination of the amount blast cells in a bone marrow sample from said subject, and/or on the determination of the number of blast cells per 1 µl in a CSF sample from said subject. According to the category into which subjects are risk-stratified, said subjects can be appropriately treated, while their risk of a potential adverse neurological reaction can be reduced or even excluded.
-
公开(公告)号：EP3831386A1
公开(公告)日：2021-06-09
申请号：EP20209362.1
申请日：2011-10-27
IPC分类号： A61K31/573 , A61K39/395 , C07K16/28
摘要： The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.
-
公开(公告)号：EP2918604B1
公开(公告)日：2017-12-20
申请号：EP15154416.0
申请日：2009-11-06
发明人： Zugmaier, Gerhard
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2809 , C07K16/3061 , C07K16/468
摘要： The present invention relates to a method for the treatment, amelioration or elimination of pediatric acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to a pediatric ALL patient in the need thereof.
-
公开(公告)号：EP4303585A3
公开(公告)日：2024-01-24
申请号：EP23192350.9
申请日：2015-05-20
发明人： Zugmaier, Gerhard , Kufer, Peter , Alekar, Shilpa
IPC分类号： G01N33/574
摘要： The present invention relates to a method for risk-stratifying subjects suffering from B-precursor acute lymphoblastic leukemia (ALL), wherein said subjects are intended for a therapy comprising administration of a CD3 binding domain. Risk-stratification is based on the determination of the amount blast cells in a bone marrow sample from said subject, and/or on the determination of the number of blast cells per 1 µl in a CSF sample from said subject. According to the category into which subjects are risk-stratified, said subjects can be appropriately treated, while their risk of a potential adverse neurological reaction can be reduced or even excluded.
-
公开(公告)号：EP4303585A2
公开(公告)日：2024-01-10
申请号：EP23192350.9
申请日：2015-05-20
发明人： Zugmaier, Gerhard , Kufer, Peter , Alekar, Shilpa
IPC分类号： G01N33/574
摘要： The present invention relates to a method for risk-stratifying subjects suffering from B-precursor acute lymphoblastic leukemia (ALL), wherein said subjects are intended for a therapy comprising administration of a CD3 binding domain. Risk-stratification is based on the determination of the amount blast cells in a bone marrow sample from said subject, and/or on the determination of the number of blast cells per 1 µl in a CSF sample from said subject. According to the category into which subjects are risk-stratified, said subjects can be appropriately treated, while their risk of a potential adverse neurological reaction can be reduced or even excluded.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.011 秒)
